Pharmaceuticals
Fibronostics Acquires Stone Clinical Laboratories to Advance MASH/MASLD Diagnostics
Acquisition expands U.S. lab operations and accelerates innovation in non-invasive diagnostics for metabolic and liver diseases. NEW ORLEANS, Oct. 27, 2025 /PRNewswire/ -- Fibronostics, a global leader in non-invasive diagnostics for metabolic and liver diseases, today announced the completion o...
2025-10-27 22:46
1125
BioDlink Completes First International Shipment of Bevacizumab to Colombia
* Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death inColombia[1]. * This inaugural shipment—dispatched around two months after Colombia's marketing approval—demonstrates the company's efficiency, while validating its ...
2025-10-27 20:30
1230
Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial
* Third Independent Data Monitoring Committee (IDMC) review confirms safety and continuation of the study * 94 patients enrolled out of 102 planned across Korea and the U.S. * Interim baseline characteristics to be presented at the 2025 KATRD International Conference SEOUL, South Korea, Oct...
2025-10-27 19:00
1144
Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
* The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group * DREAMS-3 is the world's first Phase 3 clinical trial of a GCG/GLP-1 dual receptor agonist to conduct a head-to-head c...
2025-10-27 08:00
1363
Terumo Interventional Systems Announces Its New OPUSWAVE® Dual Sensor Imaging System and DualView® Imaging Catheter Receive FDA 510(k) Clearance
* OPUSWAVE Imaging System combines OFDI and IVUS into a single catheter, providing significant potential to reduce procedural time and costs in treating coronary artery disease * DualView imaging catheter offers a 150mm maximum pullback length, a 2.6 Fr. imaging profile, 6 Fr. guide compatibi...
2025-10-24 20:00
1352
Global Launch Event for iza-bren Phase III Nasopharyngeal Carcinoma Research Results Successfully Held, Streamed on ESMO Official Website
SHANGHAI, Oct. 24, 2025 /PRNewswire/ -- At 15:00 Beijing Time (09:00 am Berlin Time) onOctober 20, the "Global Launch Event for Iza-bren (EGFR×HER3 Bispecific ADC) Nasopharyngeal Carcinoma BL-B01D1-303 Research Results" was held at the venue of the 2025 European Society for Medical Oncology (ESMO...
2025-10-24 16:40
997
HanchorBio Presents Phase 1 HCB101 Clinical Results at FACO 2025 Demonstrating Safety and Early Antitumor Activity
FACO 2025 presentation highlights HCB101's favorable safety, strong receptor occupancy, and confirmed responses in patients with advanced cancers. TAIPEI, SHANGHAI, and SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advanci...
2025-10-24 07:30
2360
METiS BioTech announces China's First AI-Enabled Formulation Drug Candidate to Complete Phase III Clinical Trial
MTS-004 Poised to Fill an Unmet Need in the Treatment of Pseudobulbar Affect (PBA) BEIJING, China, Oct. 23, 2025 /PRNewswire/ -- METiS TechBio, a global leader in AI-driven nanodelivery and formulation innovation, today announced that its internally developed small-molecule candidate MTS-004 has...
2025-10-23 21:21
1607
HanchorBio's Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology
* Prestigious peer-review validates HCB101's differentiated mechanism and translational strength. * Clinical data show a nearly 90% partial response rate in 2L gastric cancer (combo) and safe escalation to 30 mg/kg (mono) TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ -- Hanch...
2025-10-23 19:00
1999
International Youth Explore the Wisdom of Traditional Chinese Medicine Zhangshu National Pharma Fair Opens a New Chapter in Cultural Experience
ZHANGSHU, China, Oct. 23, 2025 /PRNewswire/ -- A report from Jiangxi International Communication Center (JXICC): "Without Zhangshu, medicines are incomplete; without Zhangshu, medicines lack efficacy." OnOctober 16, 2025, Jiangxi's Zhangshu Qihuang Town was bustling with crowds as the 56th Nation...
2025-10-23 14:46
1443
SynbioTech Brings Taiwan's Biotech Excellence to the Global Stage with TWK10® for Muscle Performance and Healthy Aging
LAS VEGAS, Oct. 22, 2025 /PRNewswire/ -- In a field where scientific validation defines credibility, Synbio Tech Inc., a biotechnology company fromTaiwan, is gaining international recognition with its proprietary probiotic Lactiplantibacillus plantarum TWK10®. The clinically proven strain, which w...
2025-10-23 00:00
1423
Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma
SHANGHAI, NANJING, China and PLEASANTON, Calif., Oct. 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, production, and commercialization of novel cell therapies, today announced that theBlood published the latest result...
2025-10-22 19:39
1432
LISCure BioSciences Secures World's First Approval for "Joint Health Probiotic" as Recognized Health Functional Ingredient
SEOUL, South Korea, Oct. 22, 2025 /PRNewswire/ -- LISCure BioSciences ("LISCure") announced that its proprietary joint health probiotic, JointWorks®, has been officially approved by the Korean Ministry of Food and Drug Safety (MFDS) as Recognized Health Functional Ingredient. This approval marks...
2025-10-22 14:28
1207
Renalys Pharma Announces Support for Alport Syndrome Registry Study Organized by Japanese Society for Pediatric Nephrology
TOKYO, Oct. 22, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku,Tokyo; "Renalys") is pleased to announce the company is providing financial support for the Alport Syndrome Registry Study organized by the Japanese Society for Pediatric Nephrology (Head Office: Chiyoda-ku,Tokyo). T...
2025-10-22 14:00
985
WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index
* The only company from pharmaceutical industry selected for inclusion in the Index * Also included in HSI ESG Index and Hang Seng ESG 50 Index * Green CRDMO solution provider with outstanding sustainability performance HONG KONG, Oct. 21, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a lea...
2025-10-22 08:30
2604
HanchorBio Secures US Patent for Innovative SIRPα/CD47 Fusion Protein HCB101
TAIPEI and SHANGHAI and SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ -- HanchorBio today announced that its proprietary HCB101, a SIRPα/CD47 fusion protein candidate, has been officially granted a US patent (Patent No. 12,447,195) by the United States Patent and Trademark Office (USPTO). Titled"E...
2025-10-21 19:00
1902
SK Biopharmaceuticals Launches Joint Venture with Eurofarma for AI-based Epilepsy Management Platform
SK Biopharmaceuticals forms a joint venture, Mentis Care, to develop an integrated epilepsy care ecosystem through AI-driven platform commercialization. SEOUL, South Korea, Oct. 20, 2025 /PRNewswire/ -- SK Biopharmaceuticals, Co., Ltd., a biotech company focusing on research, development, and co...
2025-10-21 09:20
1362
Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London
PISCATAWAY, N.J., Oct. 20, 2025 /PRNewswire/ -- London will become the global spotlight for cell and gene therapy (CGT) this November as Nobel Laureate, scientific leaders, biotech innovators, and top investors convene to chart the future of one of the fastest-growing fields in emerging medicine....
2025-10-20 19:43
1068
HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025
Presentations highlight HCB101's differentiated profile and introduce first preclinical data from HCB301, underscoring HanchorBio's innovation in next-generation immunotherapies TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 20, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stag...
2025-10-20 19:00
1515
Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power
BERLIN, Oct. 20, 2025 /PRNewswire/ -- From October 17 to 21, the European Society for Medical Oncology (ESMO) Annual Congress convened inBerlin, bringing together global leaders in oncology and pharmaceutical innovation. Representing China's advancing biopharmaceutical landscape, Hengrui Pharma no...
2025-10-20 14:20
1198
Week's Top Stories
Most Reposted
Agoda Launches Free Global eSIMs for VIP Diamond Members
[Picked up by 322 media titles]
2026-02-10 14:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Rockwell Automation Strengthens Industrial Cybersecurity with New Security Operations Center in Singapore
[Picked up by 298 media titles]
2026-02-09 10:00
Blackpanda Japan Announces Strategic Partnership with SoftBank to Strengthen Cyber Incident Response in Japan
[Picked up by 298 media titles]
2026-02-10 13:31Carro unveils quirky generative AI ad campaign highlighting its 'Surprisingly Short' AI-enabled car-selling process
[Picked up by 296 media titles]
2026-02-11 11:00
Most Read
Rockwell Automation Strengthens Industrial Cybersecurity with New Security Operations Center in Singapore
2026-02-09 10:00
8582
AIA RESEARCH REVEALS INGRAINED HEALTH STEREOTYPES ARE HOLDING BACK WELLBEING IN ASIA
2026-02-09 16:08
6859
Aon and KNIAZHA VIENNA INSURANCE GROUP announce new $25M war-risk insurance facility with the U.S. International Development Finance Corporation
2026-02-09 22:42
6620
Agoda Launches Free Global eSIMs for VIP Diamond Members
2026-02-10 14:00
6239
